根据最新的财务报表(Form-10K),ACRO Biomedical Co Ltd 的总资产为 $0,净损失为 $0
ACBM 的关键财务比率是什么?
ACRO Biomedical Co Ltd 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
ACRO Biomedical Co Ltd 的收入按细分市场或地理位置如何划分?
ACRO Biomedical Co Ltd 最大收入来源是 Capital Equipment,在最近的收益报告中收入为 462,059,000。就地区而言, China 是 ACRO Biomedical Co Ltd 的主要市场,收入为 363,598,000。
ACRO Biomedical Co Ltd 是否盈利?
不,根据最新的财务报表,ACRO Biomedical Co Ltd 的净损失为 $0
ACRO Biomedical Co Ltd 有负债吗?
不,ACRO Biomedical Co Ltd 的负债为 0
ACRO Biomedical Co Ltd 的流通股有多少?
ACRO Biomedical Co Ltd 的总流通股为 60.04
关键数据
前收盘价
$0.026
开盘价
$0.026
当日区间
$0.026 - $0.026
52周范围
$0.0007 - $0.1
交易量
66
平均成交量
55
股息收益率
--
每股收益(TTM)
-0.00
市值
$1.5M
什么是 ACBM?
Acro Biomedical Co. Ltd. engages in the business of developing and marketing nutritional products that promote wellness and a healthy lifestyle. The company is headquartered in Fishers, Indiana. The company went IPO on 2016-06-23. The firm is focused on developing and marketing nutritional products that promote wellness and a healthy lifestyle. The firm's business consists of selling cordyceps related products that is used in traditional Chinese medicine. Cordyceps is a fungus which is a combination of a caterpillar and a fungus, which is found at altitudes above 4500 meters (m) in Sikkim. The firm is engaged in the purchase of products from three suppliers in Taiwan and the sale of these products to four unrelated customers. The company sells products in bulk to companies who may use the Company's products as ingredients in their products or sell the products they purchase from the Company to their own customers.